• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌幸存者的极晚期复发:6例报告

Very late relapse in breast cancer survivors: a report of 6 cases.

作者信息

Omidvari Shapour, Hamedi Seyed Hasan, Mohammadianpanah Mohammad, Nasrolahi Hamid, Mosalaei Ahmad, Talei Abdolrasoul, Ahmadloo Niloofar, Ansari Mansour

机构信息

Dept. of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

出版信息

Iran J Cancer Prev. 2013 Spring;6(2):113-7.

PMID:25250120
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4142915/
Abstract

BACKGROUND

Breast cancer is the most common cancer and the leading cause of cancer death among the women worldwide. The risk of local and distant recurrence is the highest during the first two years following the initial treatment. Very late relapse (after 12 years) is uncommon in breast cancer survivors.

METHODS

Herein, we report the characteristics and outcomes of 6 such cases of breast cancer.

RESULTS

The mean age of the patients was 40.1 years (range 30-57) and the mean disease free survival was 19.6 years.

CONCLUSION

Late relapse is not so common in breast cancer but can occur in any stage. Therefore, we suggest life-time follow up for every patient with breast cancer.

摘要

背景

乳腺癌是全球女性中最常见的癌症,也是癌症死亡的主要原因。在初始治疗后的头两年,局部和远处复发的风险最高。乳腺癌幸存者中非常晚期复发(12年后)并不常见。

方法

在此,我们报告6例此类乳腺癌病例的特征和结果。

结果

患者的平均年龄为40.1岁(范围30 - 57岁),平均无病生存期为19.6年。

结论

晚期复发在乳腺癌中并不常见,但可发生于任何阶段。因此,我们建议对每位乳腺癌患者进行终身随访。

相似文献

1
Very late relapse in breast cancer survivors: a report of 6 cases.乳腺癌幸存者的极晚期复发:6例报告
Iran J Cancer Prev. 2013 Spring;6(2):113-7.
2
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
3
The influence of young age on outcome in early stage breast cancer.年轻对早期乳腺癌预后的影响。
Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33. doi: 10.1016/0360-3016(94)90515-0.
4
Patterns of breast cancer relapse.乳腺癌复发模式。
Eur J Surg Oncol. 2006 Nov;32(9):922-7. doi: 10.1016/j.ejso.2006.06.001. Epub 2006 Jul 5.
5
Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌患者早期和晚期远处复发后的生存情况
Breast Cancer. 2017 May;24(3):473-482. doi: 10.1007/s12282-016-0730-3. Epub 2016 Sep 15.
6
Local-regional breast cancer recurrence: prognostic groups based on patterns of failure.局部区域乳腺癌复发:基于复发模式的预后分组
Breast J. 2002 Mar-Apr;8(2):81-7. doi: 10.1046/j.1524-4741.2002.08202.x.
7
Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.保乳治疗早期乳腺癌中乳腺癌亚型对乳腺癌特异性生存、远处转移和局部复发率的预后价值:一项回顾性临床研究。
Eur J Surg Oncol. 2011 Oct;37(10):876-82. doi: 10.1016/j.ejso.2011.07.001. Epub 2011 Aug 6.
8
[Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].[血清Ca 15-3抗原升高:乳腺癌远处转移的早期指标。733例回顾性分析]
Przegl Lek. 2001;58(6):498-503.
9
Differences in Prognostic Factors between Early and Late Recurrence Breast Cancers.早期和晚期复发乳腺癌预后因素的差异
Asian Pac J Cancer Prev. 2015;16(15):6575-9. doi: 10.7314/apjcp.2015.16.15.6575.
10
Breast conservation treatment of early stage breast cancer: patterns of failure.早期乳腺癌的保乳治疗:失败模式
Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):765-75. doi: 10.1016/0360-3016(94)00414-5.

引用本文的文献

1
LINC00355 regulates p27 expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer.LINC00355通过与MENIN结合来调控p27表达,从而诱导晚期复发乳腺癌的增殖。
NPJ Breast Cancer. 2022 Apr 13;8(1):49. doi: 10.1038/s41523-022-00412-2.
2
A Clinicogenetic Prognostic Classifier for Prediction of Recurrence and Survival in Asian Breast Cancer Patients.用于预测亚洲乳腺癌患者复发和生存的临床遗传学预后分类器
Front Oncol. 2021 Mar 17;11:645853. doi: 10.3389/fonc.2021.645853. eCollection 2021.
3
It May Be Possible to Prevent both Early and Late Relapses in Breast Cancer; Perhaps This Is an Opportunity for Sensors or Biosensors to Help.或许有可能预防乳腺癌的早期和晚期复发;也许这是传感器或生物传感器提供帮助的机会。
Sensors (Basel). 2020 Dec 18;20(24):7261. doi: 10.3390/s20247261.
4
Caveolin-1: a multifaceted driver of breast cancer progression and its application in clinical treatment.小窝蛋白-1:乳腺癌进展的多面驱动因素及其在临床治疗中的应用
Onco Targets Ther. 2019 Feb 27;12:1539-1552. doi: 10.2147/OTT.S191317. eCollection 2019.
5
Deregulation of VEGFR-2 and PDGFR Expression and Microvascular Density in a Triple-Negative Model of Canine Malignant Mammary Tumors with Lymph Node or Lung Metastasis.犬恶性乳腺肿瘤伴淋巴结或肺转移三阴性模型中VEGFR-2和PDGFR表达及微血管密度的失调
Vet Sci. 2019 Jan 9;6(1):3. doi: 10.3390/vetsci6010003.
6
Delayed breast cancer relapse with pleural metastasis and malignant pleural effusion after long periods of disease-free survival.在长期无病生存后出现伴有胸膜转移和恶性胸腔积液的延迟性乳腺癌复发。
Respirol Case Rep. 2018 Oct 26;6(9):e00375. doi: 10.1002/rcr2.375. eCollection 2018 Dec.

本文引用的文献

1
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.转移性乳腺癌临床实践指南(第 1.2012 版):NCCN 指南的重点更新。
J Natl Compr Canc Netw. 2012 Jul 1;10(7):821-9. doi: 10.6004/jnccn.2012.0086.
2
Selective approach to radionuclide-guided sentinel lymph node biopsy in high-risk ductal carcinoma in situ of the breast.乳腺高危导管原位癌放射性核素引导前哨淋巴结活检的选择性方法。
Nucl Med Commun. 2011 Nov;32(11):1084-7. doi: 10.1097/MNM.0b013e328349eafc.
3
Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse.在可手术乳腺癌患者的随访期间,细胞角蛋白-19 mRNA 阳性循环肿瘤细胞:对晚期复发的预后相关性。
Breast Cancer Res. 2011 Jun 10;13(3):R60. doi: 10.1186/bcr2897.
4
Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome.肿瘤周围血管侵犯:三阴性乳腺癌结局的主要决定因素。
Eur J Cancer. 2011 Jul;47(10):1537-45. doi: 10.1016/j.ejca.2011.02.002. Epub 2011 Mar 8.
5
Late Recurrence of Carcinoma of Breast.乳腺癌的晚期复发
Br Med J. 1960 Oct 15;2(5206):1132-4. doi: 10.1136/bmj.2.5206.1132.
6
Low body mass index is an independent risk factor of locoregional recurrence in women with breast cancer undergoing breast conserving therapy.低体重指数是接受保乳治疗的乳腺癌女性局部区域复发的独立危险因素。
Chang Gung Med J. 2009 Sep-Oct;32(5):553-62.
7
Residual risk of breast cancer recurrence 5 years after adjuvant therapy.辅助治疗后5年乳腺癌复发的残留风险。
J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83. doi: 10.1093/jnci/djn233. Epub 2008 Aug 11.
8
Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.乳腺单纯导管原位癌与伴浸润性疾病的导管原位癌之间的基因组差异:一项校准后的比较基因组杂交研究
Clin Cancer Res. 2008 Jul 15;14(14):4446-54. doi: 10.1158/1078-0432.CCR-07-4960.
9
Time-varying pattern of recurrence risk for Chinese breast cancer patients.中国乳腺癌患者复发风险的时间变化模式。
Breast Cancer Res Treat. 2009 Apr;114(3):527-35. doi: 10.1007/s10549-008-0022-5. Epub 2008 Apr 19.
10
An overview of prognostic factors for long-term survivors of breast cancer.乳腺癌长期幸存者的预后因素概述。
Breast Cancer Res Treat. 2008 Feb;107(3):309-30. doi: 10.1007/s10549-007-9556-1. Epub 2007 Mar 22.